Zentalis Pharmaceuticals Shares Slide on Partial Clinical Holds on Cancer Drug Studies
Provided by
Dow Jones
By Adriano Marchese
Zentalis Pharmaceuticals shares were down in premarket trading after the company said partial clinical holds were placed on three of its cancer treatment studies.
Ahead of the morning bell, shares were trading nearly 27% lower at $6.15.
The clinical-stage biopharmaceutical said the U.S. Food and Drug administration has placed a partial clinical hold on studies for its drug, Azenosertib.
The company said it is working with the regulator to resolve the partial clinical hold as quickly as possible.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
June 18, 2024 07:59 ET (11:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States